wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q41544681-8D869B51-A497-437F-8BD2-D9E748C722E0
Q41544681-8D869B51-A497-437F-8BD2-D9E748C722E0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41544681-8D869B51-A497-437F-8BD2-D9E748C722E0
Comment on "combination treatment including targeted therapy for advanced hepatocellular carcinoma".
P2860
Q41544681-8D869B51-A497-437F-8BD2-D9E748C722E0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41544681-8D869B51-A497-437F-8BD2-D9E748C722E0
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
644a8b7be65d21c85759c1c2d53a04050e2156ce
P2860
Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.